Intrinsic Imaging Awarded Phase III Clinical Trial Focused on Brain Metastases of Non-Small Cell Lung Cancer (NSCLC)

Bolton, MA / San Antonio, TX — March 29, 2017 — Intrinsic Imaging, LLC, an FDA audited and ISO certified medical imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that it has been awarded another international phase III clinical trial for the evaluation of a novel treatment for metastatic non-small cell lung cancer (NSCLC) to the brain.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, study management, protocol and charter development, site qualification, site training and management, image transfer, quality control and processing. Intrinsic Imaging will also perform over 6000 neuroradiology assessments of the patients’ tumor response to therapy.

Of its team of 70 full-time radiologists, Intrinsic Imaging’s neuroradiology team consists of 9 full-time board-certified, fellowship trained neuroradiologists who are experts in the evaluation of brain metastases from various primaries including non-small cell lung cancer.

“Intrinsic Imaging’s team has extensive therapeutic experience in evaluating therapies that treat metastatic non-small cell lung cancer of the brain,” said Todd A. Joron, BSc., MBA, President & COO at Intrinsic Imaging. “Our neuroradiology experience, coupled with our exceptional operational expertise, allows us to provide unprecedented imaging core lab services on this pivotal clinical trial.”

Lung cancer is the leading cause of cancer death across the globe. Among tumor types, lung cancers account for the highest number of brain metastases, with 25% of patients being affected at some time in their disease course.